Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent.
Can biochip arrays identify which individuals with metastatic disease will respond to an anti-metastatic agent? Cytokine and cell adhesion arrays (Randox Ltd) were measured over 1 month in 9 research participants receiving CTCE-9908 in a Phase I/II study. Research participants with stable disease (n=2) had significantly higher soluble VCAM-1 as compared to those that progressed. VCAM-1 measurement early during CTCE-9908 treatment might be used as a surrogate for response.